Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapy
Author:
Funder
Pfizer
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Rheumatology
Link
https://link.springer.com/content/pdf/10.1007/s10067-020-05318-7.pdf
Reference22 articles.
1. Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9:361–371
2. Lebrec H, Ponce R, Preston BD, Iles J, Born TL, Hooper M (2015) Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk. Curr Med Res Opin 31:557–574
3. Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A, Cortelazzo S, Zoli V, Corradini P, Carobbio A, Mulé A, Bosa M, Barbui A, di Nicola M, Sorio M, Caracciolo D, Gianni AM, Rambaldi A (2011) Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 29:814–824
4. Askling J, Bongartz T (2008) Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 20:334–339
5. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Jama 295:2275–2285
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Trends in the use of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and recently diagnosed colorectal, lung, or prostate cancer;Clinical Rheumatology;2024-09-04
2. Survival in patients with rheumatoid arthritis and early breast cancer treated with tumor necrosis factor inhibitors;Breast Cancer;2024-08-08
3. Clinical practice guidelines for the early detection, diagnosis, treatment, and follow-up of patients with rheumatoid arthritis. Colombian Association of Rheumatology, 2022;Revista Colombiana de Reumatología (English Edition);2024-04
4. Utilization of Biologic Disease‐Modifying Antirheumatic Therapy in Patients With Rheumatoid Arthritis and Recently Diagnosed Breast Cancer;Arthritis Care & Research;2024-03-06
5. Use of Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis: Supporting Shared Decision‐Making Between Patients With Cancer and Clinicians;ACR Open Rheumatology;2023-05-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3